- Home
- BYD vs PTGX Comparison
BYD vs PTGX Comparison
Compare BYD & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYD | PTGX |
|---|---|---|
| Founded | 1973 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.4B |
| IPO Year | 1993 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BYD | PTGX |
|---|---|---|
| Price | $80.23 | $90.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $89.57 | $88.33 |
| AVG Volume (30 Days) | 722.3K | ★ 872.1K |
| Earning Date | 10-23-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ 325.66 | N/A |
| EPS | ★ 22.22 | 0.72 |
| Revenue | ★ $4,070,839,000.00 | $209,217,000.00 |
| Revenue This Year | $2.59 | N/A |
| Revenue Next Year | N/A | $296.47 |
| P/E Ratio | ★ $3.59 | $125.31 |
| Revenue Growth | ★ 5.91 | N/A |
| 52 Week Low | $58.94 | $33.70 |
| 52 Week High | $88.49 | $93.25 |
Technical Indicators
Market Signals| Indicator | BYD | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 66.61 |
| Support Level | $81.62 | $83.52 |
| Resistance Level | $82.89 | $90.85 |
| Average True Range (ATR) | 1.55 | 2.74 |
| MACD | -0.06 | -0.14 |
| Stochastic Oscillator | 36.46 | 76.62 |
Price Performance
Historical ComparisonAbout BYD Boyd Gaming Corporation
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. Midwest and South hold the key number of entertainment properties, and it generate the majority of sales for the company.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.